The global cystic fibrosis therapeutics market size is estimated to reach USD 22.7 billion by 2030, expanding at a CAGR of 14.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of Cystic Fibrosis (CF) globally, research development activities undertaken by key players, and favorable initiatives undertaken by nonprofit organizations are expected to boost the market over the forecast period.

The rising prevalence of CF indicates the rising demand for treatment alternatives, thereby uplifting the market. The key players operating in this market in collaboration with nonprofit organizations focus on the development of novel therapeutics for treatment. Some of the drugs that are under clinical studies are VX-445 + tezacaftor + ivacaftor, PTI-428, QR-010, AZD5634, and POL6014.

Favorable initiatives taken by regional and national nonprofit organizations is one of the key factors propelling growth. These initiatives ensure support to CF patients. These organizations aid in research development activities of these therapeutics and help improve the quality of life of these patients. For instance, North American Cystic Fibrosis Conference (NACFC) was formed in 1986 to provide a collaborative and educational forum to CF professionals to share advances in RD related to CF therapeutics.

Cystic Fibrosis Therapeutics Market Report Highlights

• The global CF therapeutics market size was estimated at USD 10.3 billion in 2024 and is expected to grow at a CAGR of 14.2% from 2025 to 2030
• CFTR modulators dominated the market and accounted for the largest revenue share of 44.0% in 2024 owing to the approval of CFTR modulator, Orkambi and the presence of various investigational compounds under the pipeline.
• The growth of oral administration led the market and accounted for the largest revenue share of 69.0% in 2024 due to the ease of administration and convenience
• North America accounted for the largest market share owing to the presence of Caucasian descents in this region. Improved healthcare infrastructure, reimbursements, and initiatives undertaken by the nonprofit organizations is expected to propel the market over forecast period,
• The key players include AbbVie Inc., F. Hoffmann-La Roche Ltd.; Gilead, Novartis AG, Vertex Pharmaceuticals Inc., AIT (Advanced Inhalation Therapies), Alaxia, Teva Pharmaceutical Industries Ltd, Merck Co. Inc., Alcresta Therapeutics Inc., Allergan, and AstraZeneca

Cystic Fibrosis Therapeutics Market Segmentation

Grand View Research has segmented the global cystic fibrosis therapeutics market based on drug class, route of administration, distribution channel, and region:

Cystic Fibrosis Therapeutics Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• CFTR Modulators
• Pancreatic Enzyme Supplements
• Mucolytics
• Bronchodilators

Cystic Fibrosis Therapeutics Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral
• Inhaled

Cystic Fibrosis Therapeutics Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Cystic Fibrosis Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Russia
• Asia Pacific
  • India
  • China
  • South Korea
  • Hong Kong
  • Australia
  • Singapore
  • Japan
  • New Zealand
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • Kuwait
  • Qatar
  • Saudi Arabia
  • South Africa
  • UAE

Order a free sample PDF of the Cystic Fibrosis Therapeutics Market Intelligence Study, published by Grand View Research.